INTRODUCTION

Nowadays cardiovascular pathology and diabetes represent a significant medical and social problem due to the serious consequences for health, work efficiency, life expectancy and life quality of patients [1]. Diabetes mellitus is an independent risk factor for cardiovascular diseases. At the same time, cardiovascular complications are the major cause of death in patients with type 2 diabetes [2]. At the same time, the risk of developing heart failure in patients with type 2 diabetes increases 2-4 times [3, 4]. This leads to a significant increase in the frequency of hospitalization and a pronounced deterioration in prognosis: 5-year survival in comorbidity of heart failure and type 2 diabetes does not exceed 25% [5, 6, 7]. The urgent task is to look for preventative measures of heart failure in patients with type 2 diabetes. It includes the improvement of glucose-lowering therapy, namely the use of drugs that do not only improve glycaemic control but also reduce the risk of cardiovascular diseases and heart failure. Recently, an arsenal of agents for the treatment of type 2 diabetes has been supplemented with sodium-glucose co-transporter 2 inhibitors. They are associated with a decrease in glucose reabsorption in the proximal tubules of the kidneys, provided that the glomerular filtration rate is maintained.

THE AIM

is to study the possibilities of increasing the efficiency of prevention of cardiovascular diseases and heart failure when using a new class of glucose-lowering agents – sodium-glucose co-transporter 2 inhibitors.

MATERIALS AND METHODS

The analysis of the existing clinical and experimental data on the effect of SGLT-2 inhibitors on the cardiovascular system, kidney status, risk factors for cardiovascular complications.

REVIEW AND DISCUSSION

The study of new pathogenetic mechanisms responsible for maintaining chronic hyperglycaemia has led to the creation of a promising class of glucose-lowering agents that reduce plasma glucose by inhibiting glucose reabsorption in the proximal tubules of kidneys without hypoglycaemia [8]. Due to its mechanism of action, SGLT-2 inhibitors are not only able to improve glycaemic control but also to provide cardioprotective and nephroprotective effects in patients with type 2 diabetes and high cardiovascular risk.
The EMPA-REG OUTCOME study evaluated the effects of oral intake of 10 and 25 mg of empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes and high cardiovascular risk. The results have shown a 14% reduction in the risk of serious side cardiovascular events (severe cardiovascular event; non-fatal myocardial infarction; non-fatal stroke and mortality from cardiovascular disease), a decreased risk of cardiovascular mortality by 38% and overall mortality by 32%, hospitalization frequency with heart failure by 35% on receiving empagliflozin compared with placebo [9]. A low risk of acute heart failure was observed in patients receiving empagliflozin with a history and without a history of heart failure [10]. The favorable effect of empagliflozin on reducing deaths and hospitalizations due to heart failure was common in patients throughout the observation period and after discontinuation of the drug (up to 3.1 years). Both doses of empagliflozin (10 mg and 25 mg) had similar effects on cardiovascular outcomes, so this effect was not dose-dependent. Besides the effects on cardiovascular risk, based on additional data from EMPA REG-Outcome, it has been shown that the addition of empagliflozin to the standard therapy significantly slowed the development and progression of kidney damage in patients both without albuminuria and with microalbuminuria and had the greatest effect on patients with the most severe course of nephropathy (existing macroalbuminuria) [11].

Prior to the publication of the results of the EMPA-REG study, the ability to improve the prognosis of patients with heart failure had not been proven for any of the glucose-lowering agents, moreover, some of these agents can impair it [12].

Positive results of SGLT-2 inhibitors were also obtained in another clinical trial program, CANVAS, which examined the safety and efficacy of canagliflozin in patients with type 2 diabetes who had a history of cardiovascular events (65%) or with a high cardiovascular risk (35%). Adding canagliflozin to the standard therapy not only reduced blood pressure and body weight, but also reduced the rate of hospitalization for heart failure by 33%. The drug also showed a nephroprotective effect due to its ability to slow albuminuria progression by 27% and increase albuminuria regression by 70%. The level of an estimated glomerular filtration rate was stable in the main canagliflozin group whereas it decreased in placebo patients [13].

A large international SVD-REAL study evaluating the data of more than 300,000 diabetic patients (87% of patients did not have cardiovascular disease at the beginning of the study) has demonstrated that SGLT-2 inhibitors compared to other diabetes medications are associated with a 39% relative reduction in the risk of hospitalization for heart failure and overall mortality by 51% [14]. In another CVD-REAL2 international study, the use of SGLT-2 inhibitors was associated with a 49% reduction in the risk of death and a 36% reduction in the risk of hospitalization for heart failure [15]. It should be noted that the vast majority of patients in this study did not have a diagnosis of cardiovascular disease. Therefore, the findings in the CVD-REAL and CVD-REAL2 studies regarding the cardiovascular benefits of SGLT-2 inhibitors can be extrapolated to a broader population of patients with diabetes.

It is not yet fully understood what underlies the cardioprotective action of SGLT-2 inhibitors. These mechanisms are most likely not associated with glycaemia reduction. A number of additional effects of SGLT-2 inhibitors (the so-called pleiotropic non-hypoglycaemic effects) may be viewed on the example of empagliflozin. It is broadly accepted that patients with diabetes are known to be characterized by an excess of Na+, due to its increased reabsorption in the kidneys by hyperglycaemia, hyperinsulinemia, activation of the renin-angiotensin-aldosterone system, etc. [16].

The delay of Na+ and water plays an important role in increasing the preload and afterload of the heart, leading to the development of peripheral oedema and stagnation of blood in the lungs, and eventually to hospitalization. In this case, the excess of Na+ is distributed not only in extracellular space, but also inside cells. The excessive content of Na+ inside cardiomyocytes increases the risk of arrhythmia in the experiment and may lead to impaired myocardial function, in particular through impaired mitochondrial function [17].

Empagliflozin has the properties of an osmotic diuretic and enhances natriuresis. By reducing the volume of blood plasma, it helps to achieve euvaolic state and lower overload on the ventricles of the heart and, consequently, reduce the volume overload of the heart, which can play a role in reducing the risk of arrhythmias and arrhythmic death. Reduction of peripheral vascular resistance and blood pressure can reduce cardiac afterload, improve coronary blood flow and myocardial contractility. Among the important additional advantages there are the lack of activation of the sympathetic nervous system and the absence of changes in potassium levels, since the occurrence of hyperkalaemia leads to a decrease in the positive effect of diuretic therapy on the frequency of cardiovascular events [18]. This may attribute empagliflozin to diuretics with unique properties, and it is likely that SGLT-2 inhibitors will be more in demand, cardiology included, than conventional diuretic therapy after further large-scale studies.

Several studies have shown that SGLT-2 inhibitors cause a decrease in systolic blood pressure in the range of 3-5 mm Hg and diastolic blood pressure – 2-3 mm Hg, reduce the pulse pressure and the average blood pressure [19]. In particular, in the EMPA-REG Outcome study, the reduction in systolic blood pressure after empagliflozin was 4 mm Hg, while diastolic blood pressure was 2 mm Hg, which was not accompanied by an increase in heart rate. This leads to the conclusion that there is no compensatory reflex activation of the sympathetic nervous system and suggests the effect of SGLT-2 inhibition on the reduction of the stiffness of the arterial vessel wall. Thus, the use of empagliflozin in young patients with an uncomplicated course of type 1 diabetes [20] led to a decrease in systolic blood pressure (an average of 2.7 mm Hg). It was also noted that the drug reduced the speed of the pulsatile wave and of the radial artery.
Therefore, reducing the incidence of cardiovascular complications and mortality in patients with type 2 diabetes compared with other diabetes-reducing agents or placebo may primarily be related to the hemodynamic effects of SGLT-2 inhibitors [21, 22, 23], which reduce preload and afterload, vascular stiffness, which improves left ventricular function and leads to a decrease in myocardial oxygen consumption.

In people with type 2 diabetes, SGLT-2 inhibitors, in addition to the antihypertensive effect, have caused dose-dependent weight loss as a result of the osmotic diuretic effect and loss calories for glucosuria [24, 25, 26] – excretion of 50-80 g of glucose a day stands for losing 200-300 kcal. In addition, another important aspect is a lower level of insulin, which is for its anabolic effects, as well as an increased risk of hypoglycaemia does not increase depending on the basic insulin. The influence of SGLT-2 inhibitors on visceral fat is pointed out by 2 kg, resulting in a decrease in waist by 2 cm. The influence of SGLT-2 inhibitors on visceral fat is of a special interest. The latter is associated with a higher degree of probability of type 2 diabetes development, cardiovascular complications and death [29].

Among the beneficial extraglcaemic effects of SGLT-2 inhibitors there is a glucose-dependent decrease in urate reabsorption [30]. SGLT-2 inhibitors increase the excretion of uric acid and reduce its plasma concentration by 10-15%, which within the EMPA-REG OUTCOME is 24 μmol/l. For a long time, hyperuricemia was not only considered as a component of the metabolic syndrome, but was also associated with the decrease in cardiovascular diseases [31]. The accumulated data, both in humans and in experimental models, illustrate that the increased plasma level of uric acid may lead to arterial hypertension, endothelial vascular dysfunction, congestive heart failure, and kidney dysfunction [32].

The decrease in uric acid levels can hardly explain the rapid improvement in cardiovascular outcomes demonstrated by empagliflozin compared to placebo. Nevertheless, this effect may play a certain role in reducing cardiovascular mortality at a later period of drug administration and slow down the progression of diabetic nephropathy.

Empagliflozin does not increase the incidence of hypoglycaemia regardless of baseline glycated hemoglobin (HbA1c) concentration, which gives an opportunity to improve cardiovascular prognosis without increasing the risk of hypoglycaemia. The second benefit is that the risk of hypoglycaemia does not increase depending on the basic therapy. It should be emphasized that the mechanism of action of SGLT-2 inhibitors is insulin-independent. Therefore, SGLT-2 inhibitors can be used at any stage of type 2 diabetes, in particular, in the depletion of beta-cellular apparatus of the pancreas. Thus, they can be combined with other anti-hyperglycaemic drugs, since their mechanisms are different from the mechanisms of action of other currently available classes of drugs [33]. SGLT-2 inhibitors are the only class of glucose-lowering agents, other than metformin, that are, without any limitation, compatible with basal insulin. The addition of SGLT-2 inhibitors to the therapy regimen helps to improve glycemic control with a lower insulin dose.

Numerous data have convincingly shown that chronic kidney disease resulting from diabetic nephropathy is an important and independent risk factor for cardiovascular pathology. Population studies have shown that a combination of the chronic kidney disease and type 2 diabetes in a patient significantly increases the incidence of cardiovascular complications. However, albuminuria has also been identified as a risk factor for death from a cardiovascular disease. The analysis of a numerous randomized placebo-controlled clinical trials, including EMPA-REG OUTCOME, CANVAS, has shown that SGLT-2 inhibition can cause both cardiovascular and renoprotective effects [34, 35, 36, 37].

SGLT-2 inhibitors have been proven to prevent impaired glomerular filtration and reduce the degree of albuminuria in patients with diabetes-related kidney disease. In the Renal branch of the EMPA-REG OUTCOME study, there was a significantly lower risk of progression to macroalbu minuria or other clinically relevant renal outcomes, such as doubling of serum creatinine levels and initiation of renal replacement therapy in patients from the empagliflozin group in comparison to the placebo one. Thus, the obtained results allow us to confidently attribute empagliflozin to drugs with a nephroprotective action. The mechanism of nephroprotective action of empagliflozin, apparently, is not only due to the decrease in glycaemia, but also due to the non-glycaemic effects in the form of weight loss, decrease in blood pressure and stiffness of the arterial wall, correction of intrarenal hemodynamics, increase of natriuresis. Nephroprotection can be associated with the direct effect of empagliflozin on inflammatory processes, since inflammation, fibrosis and oxidative stress are closely related to intracellular hypertension [38]. The results of in vitro and in vivo studies suggest that inhibition of SGLT-2 slows the activity of these processes [39]. However, in studies with empagliflozin, inflammatory markers have not been evaluated, although there is some evidence that C-reactive protein reduced dapagliflozin [40]. This will possibly be the subject of the further study. The results of studies on the prospects of using SGLT-2 inhibitors for the treatment of heart failure in individuals without diabetes will also be of great interest.

**CONCLUSIONS**

1. When choosing glucose-lowering agents in patients with diabetes, it is necessary to consider their impact on the risk of development and the course of heart failure.
2. SGLT-2 inhibitors should be considered as a preferred method of treatment for diabetes in patients with heart failure or with a risk of heart failure, which meets the recent recommendations of the European and American Diabetes Association.
REFERENCES


**ORCID and contributionship:**

Maryana M. Rosul – 0000-0002-2106-5386 \(^{A,B,D}\)

Myroslava M. Bletskan – 0000-0002-8069-6145 \(^{A,B,D}\)

Natalia V. Ivanio – 0000-0003-0147-2176 \(^{R,F}\)

Marina O. Korabelshykova – 0000-0002-7632-4322 \(^{R,F}\)

Yelyzaveta I. Rubtsova – 0000-0001-9395-1822 \(^{E,F}\)

**Conflict of interest:**
The Authors declare no conflict of interest.

**CORRESPONDING AUTHOR**

Maryana M. Rosul
State Higher Educational Establishment "Uzhhorod National University", Uzhhorod, Ukraine
tel: +380506115733
e-mail: maryana.rosul@uzhnu.edu.ua

**Received:** 17.01.2020

**Accepted:** 05.03.2020

**A** – Work concept and design, **B** – Data collection and analysis, **C** – Responsibility for statistical analysis, **D** – Writing the article, **E** – Critical review, **F** – Final approval of the article